Although still controversial, the presence of mutant p53 in cancer cells may result in more aggressive tumors and correspondingly worse outcomes. The means by which mutant p53 exerts such pro-oncogenic activity are currently under extensive investigation and different models have been proposed. We focus here on a proposed mechanism by which a subset of tumor-derived p53 mutants physically interact with p53 family members, p63 and p73, and negatively regulate their proapoptotic function. Both cell-based assays and knock-in mice expressing mutant forms of p53 support this model. As more than half of human tumors harbor mutant forms of p53 protein, approaches aimed at disrupting the pathological interactions among p53 family members might be of clinical value.
Introduction
The p53 tumor suppressor plays a central role in regulating cell cycle and apoptosis. Under a variety of stress conditions, wild-type p53 protein quickly accumulates in the nucleus and can then transcriptionally regulate a number of downstream genes that control cell cycle arrest or apoptosis (reviewed by Vogelstein et al., 2000; Laptenko and Prives, 2006) . In addition, wild-type p53 can contribute to apoptosis through transcriptionindependent pathway(s) in the cytosol (reviewed by Chipuk and Green, 2006) . Loss of p53 function inevitably promotes tumorigenesis and also renders tumor cells resistant to chemo-and radiotherapy.
There are several lines of evidence that p53 functions as a canonical tumor suppressor. Notably p53-null mice acquire tumors early with 100% penetrance, highly cancer-prone Li-Fraumeni families carry germline mutant forms of p53, and p53 is among the most commonly mutated genes in all human cancers. In contrast to other tumor suppressors that undergo large deletion or frameshift mutations resulting in their lack of expression, however, many tumor-derived p53 mutations are of the missense variety. These mutations are usually located within the central conserved region of p53 that binds to DNA in a sequence-specific manner and result in either direct loss of DNA contact or gross change of the conformation that no longer permits p53 to recognize its wild-type DNA targets (reviewed by Vousden and Lu, 2002) . Approximately 30% of these tumor-derived p53 mutations affect only six 'hot-spot' residues (175, 245, 248, 249, 273 and 282) . In many cases tumor-derived p53 mutants are expressed at far higher levels than wild-type p53 protein due in part to their failure to be degraded by Mdm2. Related to this, many experimental and clinical lines of evidence suggest that tumor-derived p53 mutants have acquired novel functions that promote cancer cell growth. The underlying mechanisms by which these gain-of-function p53 mutants act, a subject of intense study, can be at multiple levels. For example such mutants might upregulate a specific set of genes promoting cell growth and/or inactivate distinct sets of genes that have tumor suppressor activity. Indeed, according to one model different p53 mutants might each display unique properties in regulating gene expression (Resnick and Inga, 2003) . We discuss in this review a hypothesis to explain how mutant p53 promotes pro-oncogenic activities which posits that some mutant p53 proteins can interact with and downregulate the transcriptionally active forms of the p53 homologues, p63 and p73, leading to reduced apoptotic response and radioresistance in tumor cells. Evidence to support this hypothesis is described and discussed below.
The p53 gene family consists of three members p53, p63 and p73 that are homologous in three domains: their N-terminal transcriptional activation domain (TAD), central core sequence-specific DNA-binding domain (DBD) and the C-terminally located oligomerization domain (OD). P63 and p73, which generally share more homology with each other than with p53, can be expressed as two N-terminal isoforms that either contain (TA) or lack (DN) a full TAD through alternate promoter usage and these two isoforms in turn can each have multiple C-termini generated as a result of alternative splicing. In general, the full-length TA versions of p63/p73 can exert p53-like activities, whereas the DN versions have the opposite effect (reviewed by Yang et al., 2002) . More recently it was reported that p53 can also be expressed as multiple isoforms differing in N and C-termini (reviewed by Murray-Zmijewski et al., 2006) . The different p53 C-termini, however, are quite distinct from those of p63 and p73.
It is still unclear whether and to what extent p63 and p73 play roles in tumor suppression. p63 and p73 knockout mice display defects in development rather than increased tumorigenesis. Furthermore, p63/p73 mutations are not commonly observed in human tumors. Nevertheless, several lines of evidence suggest that p63 and p73 can also mediate cellular responses to DNA damage agents and have potential tumor suppression activity in vivo. First, when overexpressed, TAp63/ p73 can activate a number of common p53 responsive genes involved in cell cycle arrest and apoptosis (Kaghad et al., 1997; Osada et al., 1998; Yang et al., 1998; Wu et al., 2003; Lokshin et al., 2005) . Second, endogenous TAp73 can be stabilized by DNA-damaging agents and its ablation can result in chemoresistance (Bergamaschi et al., 2003; Irwin et al., 2003; Urist et al., 2004) . Although less explored, endogenous TAp63 can also determine chemotherapeutic efficiency (Gressner et al., 2005) . Third, Flores et al. (2002) showed that p63 and p73 are required by p53 to activate a few proapoptotic genes in mouse embryo fibroblasts (MEFs) expressing adenoviral E1A. Finally, in one genetic background mice heterozygous for p63 and p73 can develop tumors (Flores et al., 2005) . Nevertheless, in contrast to p63 or p73, the central role of wild-type p53 in protection from cancer is unequivocal.
A subset of p53 mutants can interact with p63 and p73
Biochemical studies have revealed that the tetramerization domains of p63 and p73 can hetero-oligomerize with each other but neither can form heterotetramers with p53 (Davison et al., 1999) . Despite this it has been shown that a number of p53 mutants can associate with either p73 or p63 as evidenced by co-immunoprecipitation assays when they are either ectopically or endogenously expressed (Di Como et al., 1999; Marin et al., 2000; Strano et al., 2000 Strano et al., , 2002 Gaiddon et al., 2001; Bergamaschi et al., 2003; Irwin et al., 2003) . Both 'conformation' mutants (e.g. R175 and G245) and 'contact' tumor derived p53 mutants (e.g. R248, R273, R283) have been reported to associate with p63/p73. Furthermore, purified mutant p53 and p63/p73 can bind to each other in vitro, strongly indicating that such interaction is direct (Gaiddon et al., 2001; Strano et al., 2002) . Although only a subset of p53 mutations have been tested so far, the fact that some hot-spot mutants are capable of interacting with and inactivating p63/p73 suggest that a significant portion of mutant p53 proteins in tumors could participate in complexes with the p53 family members.
Interestingly the interaction between mutant p53 and p63/p73 is very likely to be through their respective central conserved core domains. Deletion analyses have shown that the core domain of mutant p53 alone is sufficient to bind p63 or p73 both in vivo and in vitro (Strano et al., 2000 (Strano et al., , 2002 Gaiddon et al., 2001) . Moreover, either a construct expressing the p73 core DNA binding and OD, or one expressing just the DBD of p63, can associate with mutant p53 (Strano et al., 2000 (Strano et al., , 2002 . As p63 and p73 are most homologous to each other in their core domains and they were shown to bind to the same subset of p53 mutants, it is likely that their core domains are the critical if not sole binding surface for mutant p53.
How might such interactions occur? A number of results collectively suggest that conformational changes in the p53 core domain are responsible for its interaction with p63/p73. First, most p53 hot-spot mutants undergo structural changes in the DBD as determined by nuclear magnetic resonance spectroscopy (Wong et al., 1999) . There is also a strong correlation between the ability of mutant p53 to interact with p63/p73 and their reactivity to the conformation sensitive monoclonal antibody PAb240 (Gaiddon et al., 2001 ). This antibody recognizes a cryptic epitope within the core domain when p53 is unfolded and therefore reflects an altered conformation of the protein (discussed by Cho et al., 1994) . Moreover, wild-type Xenopus laevis p53 protein that was shown to be intrinsically temperature sensitive at 371C, binds to both human p73 and the heat-shock protein hsp70 in a temperature-dependent manner (Bensaad et al., 2003) . In fact, some p53 mutants with conformational distortion can associate with hsp70 protein (Gannon et al., 1990) and some of these can also interact with p73 (Gaiddon et al., 2001) . Furthermore, immunopurified wild-type p53 protein contains a fraction that is conformationally changed during the procedure and is both recognized by PAb 240 and can interact with p73 (Gaiddon et al., 2001) . In addition, wild-type p53 prepared under harsh conditions or upon repeated freeze and thaw cycles that partially denature proteins can associate with p73 (Bensaad et al., 2003) .
Despite indications that the main determinant for interaction with p63 and p73 is an unfolded p53 core domain there are many observations suggesting that this conclusion may be an oversimplification. For example, unlike full-length p53, several versions of truncated wild-type p53 can interact with p73 when they are coexpressed in insect cells (Gaiddon et al., 2001) . These include p53 variants with a wild-type core domain but lacking either the OD, the N-terminal 96 amino acids or the C-terminal 30 amino acids, suggesting that such deletions could impose long range influence on the conformation of the core domain. Even though it is assumed that p53 contact mutants disrupt protein-DNA interactions without gross conformational changes, some of the contact mutants are capable of interacting with p63/p73 (e.g. R248, R273, R283). They too may exhibit subtle structural distortion to expose a binding site for p63/p73. Indeed the R248 mutation has been found to alter the structure of the DBD (Wong et al., 1999) . Most intriguingly two groups have reported that the binding affinity of mutant p53 for p73 (as well as p63) is affected by a common p53 polymorphism at codon 72 (R72 or P72; Marin et al., 2000; Bergamaschi
The physical and functional interaction between mutant p53 and p63/p73 Y Li and C Prives et al., 2003). These studies indicate that p53 mutants with R72 can associate with p73 more efficiently than the same mutants harboring P72. Further studies are needed to investigate whether the codon 72 polymorphism has a direct impact on the core domain conformation, makes an additional contact with p73, or requires other proteins in the cell to mediate the effect. It will be crucial to determine whether purified mutant p53 proteins with either codon 72 polymorphism can interact differently with purified p63/p73 proteins in vitro. As others have not observed a similar correlation, it is possible that multiple determinants such as cell type might modulate the influence of this polymorphism (Gaiddon et al., 2001; Willis et al., 2003) .
What remains to be determined is the nature of the surfaces on the unfolded mutant p53 core domain that make contact with p63 and p73 and whether the regions of the wild-type p63 and p73 cores that interact with mutant p53 are distinct from that of wild-type p53. It may be relevant that the core domains of wild-type p53 and p73 display significant differences in the exposures of their cysteine residues and their ability to bind zinc (Lokshin et al., 2007) .
Mutant p53 interactions with p63 and p73 have functional outcomes
Whatever the structural basis for the association of mutant p53 with its homologues, several studies have documented decreased transcriptional activities of p63/p73 and their ability to induce growth suppression and apoptosis when in the presence of mutant p53 (Di Como et al., 1999; Marin et al., 2000; Strano et al., 2000 Strano et al., , 2002 Gaiddon et al., 2001; Bergamaschi et al., 2003) . Importantly, these studies have indicated a good correlation between the efficiency of binding to and inactivation of p63/p73 by mutant p53. As mutant p53 interacts with the core DBD of p63/p73, it is conceivable that p63 and p73, when bound to mutant p53, might be inefficient at recognizing their own DNA targets, as was previously reported using a DNA-binding electrophoretic mobility shift assay (Marin et al., 2000; Strano et al., 2000) . Moreover, using a chromatin immunoprecipitation assay, it was demonstrated that the recruitment of endogenous p63 to its target genes such as p21, 14-3-3s and bax is impaired in cells expressing either endogenous or ectopic mutant p53 (Strano et al., 2002) .
Taking these findings into a more physiological context, results from two groups support the possibility that mutant p53 can hamper the cellular chemoresponse through inhibiting endogenous p63 or p73 (Bergamaschi et al., 2003; Irwin et al., 2003) . Specifically, a number of human tumor cell lines are more resistant to chemotherapeutic drugs when they express ectopic or endogenous mutant p53 capable of binding to p73. Importantly, cells with those p53 mutants that can bind better to p73 usually have a higher resistance to chemotherapeutic drugs. Reciprocally, downregulating the expression of mutant p53 using small-interfering RNA (siRNA) enhances the cellular response to drug-induced cell death. Although future studies are required to find out the extent of the contribution of p63 and p73 to this increased chemosensitivity, these reports have provided a plausible link between mutant p53 binding to p73 and a decreased chemosensitivity of cells. Taking this further, a clinical study showed a correlation between the codon 72 polymorphism in p53 mutants and the therapeutic response of a subset of head and neck cancers (Bergamaschi et al., 2003) . Tumors in those patients who responded worse to chemoradiotherapy generally retain the R72 version of mutant p53 that binds better to p73. It is acknowledged that the clinical data implicating the R72 variant as being more deleterious could result from other properties that this change confers upon mutant p53, just as it has with wild-type p53.
Two studies using mouse models have also provided important corroborating evidence in vivo showing that mutant p53 promotes tumorigenesis and that it may do so through downregulating its p53 family members (Lang et al., 2004; Olive et al., 2004) . These groups generated p53 mutant mice with mutation at codon 170 (Lang et al., 2004; Olive et al., 2004) as well as codon 270 (Olive et al., 2004) . These are the murine equivalents of human p53 R175H and R273H hot-spot mutants, respectively. Importantly, mutant p53 knock-in mice have different phenotypes from the p53 knockout mice in terms of tumor spectrum and increased metastasis. Some of their new phenotypes are reminiscent of those seen in mice losing one copy of both p53 and p63/p73, and therefore could be in part owing to the inactivation of p63/p73 pathway by mutant p53 in vivo (Flores et al., 2005) . This hypothesis is supported by the following experiments. First, mutant p53 proteins were found to be associated with endogenous p63 and p73 in tumor cells from these mutant p53 mice (Lang et al., 2004; Olive et al., 2004) . Second, silencing of mutant p53 expression in these tumor cells stimulated the expression of p53 family target genes, most likely reflecting an enhanced activity of endogenous p63/p73 in the absence of mutant p53 (Lang et al., 2004) . Third, downregulation of p63/p73 in p53-null MEFs stimulated DNA synthesis and transformation potential to levels similar to those in mutant p53 MEFs (Lang et al., 2004) . It is relevant that loss of p63 has been recently shown to upregulate genes involved in invasion and metastasis (Barbieri et al., 2006) . This could in part explain the reasons for the increased metastasis observed in mice expressing mutant p53.
Mutant p53 and p63/p73: what lies ahead?
As described above a significant body of work suggests that some of the common forms of mutant p53 might exert their pro-oncogenic activity in part through their interactions with p63 and p73. To further understand the relationship between mutant p53 and p63/p73 the following questions might be worthy of future investigation.
The physical and functional interaction between mutant p53 and p63/p73 Y Li and C Prives How many molecules of mutant p53 are required to inactivate p63/p73? Although the answer to this is as yet unclear, as noted above, mutant forms of p53 often accumulate to high levels in tumor cells. It is conceivable that a high ratio of mutant p53 to p63/p73 is required for the inhibitory role of mutant p53. It is therefore important to assess how much p63 or p73 protein is normally present in tumor cells. In fact, in HCT116 cells, where this was carefully assessed, endogenous wild-type p53 is present at about a 20-to 30-fold molar excess over wild-type p73 even after treatment of cells with DNA-damaging agents that lead to increased levels of both proteins (Lokshin et al., 2005) . Additionally, we have found that in human immortalized keratinocytes (HaCat) mutant p53 is present at greater than a 20-fold excess over p63 (Li, Neusch and Prives, unpublished data). In support of this, at least half of the endogenous p73 in HaCat cells was found to bind to mutant p53, whereas only a small portion of the mutant p53 associates with p73, suggesting that mutant p53 is more abundant than p73 in the cell (Marin et al., 2000) . It is therefore likely that a considerable surfeit of mutant p53 is needed for it to sequester the majority of p63 or p73. This may account for the observations of Willis et al. (2003) who, using an elegant dual inducible promoter system to express both wild-type p73 and mutant p53 (R175H), failed to see an inhibitory effect of mutant p53 on p73b over a range of mutant p53/p73 ratios. Possibly they did not reach the same ratio of mutant p53 to p73 experimentally as found in some tumor cells. Further, the cells they used (H1299 cells) may be unique in requiring massively higher amounts of mutant p53 obtainable only by transient transfection.
Can the DN p63/p73 isoforms be regulated by mutant p53?
The assumption that mutant forms of p53 bind to the core domains of p63 and p73 leads to a potentially complicated scenario. The above-mentioned inhibitory effects of mutant p53 were shown to act upon the TA isoforms of p63 and p73 that are proapoptotic. It remains to be addressed whether mutant p53 can also inhibit the function of DN p63/p73 proteins. If this were the case then one would have to take into account the fact that DN p63/p73 proteins can have pro-proliferative and possibly oncogenic activity. In fact, DNp63, like some p53 mutants, promotes the survival of squamous cell carcinoma (SCC) by blocking the TAp73 pathway (Rocco et al., 2006) . In addition, many SCC cells express both mutant p53 and DNp63 (Hibi et al., 2000) . Moreover, one recent study revealed that the hot-spot R175H mutant p53 can induce the expression of DNp63 after a subset of DNA damage treatment including doxorubicin (Lanza et al., 2006) . This phenomenon seems to be mediated by CCAAT box and NF-Y protein, and is consistent with another study showing that mutant p53 can interact with NF-Y transcription factors to stimulate the expression of proliferative cell cycle genes after DNA damage (Di Agostino et al., 2006) . Regardless, in one experimental setting overexpressed DNp63 had much lower binding affinity than TA p63 to mutant p53 (Gaiddon et al., 2001) . If this is a general phenomenon, it implies that there may be sequences outside of the core domain that are unique to the TA isoforms of p63 and p73 that facilitate their interaction with mutant p53 or alternately that the short sequence unique to the DN isoform weakens its interactions with mutant p53. It also suggests the possibility of unifying the current possible modes by which mutant p53 proteins can act. They can directly promote pro-proliferative gene expression through their interactions with NF-Y proteins and inhibit the anti-proliferative properties of the TA p63/p73 without hampering the opposing activity of their DN counterparts. There are clearly some important experiments that need to be performed to further elucidate the relationship between mutant p53 and the different isoforms of p63 and p73.
Do mutant p53 proteins affect the ability of p63/p73 to interact with other proteins that regulate their activities? A plethora of binding partners have been identified that interact with p53 and a growing number of proteins have also been found to bind to p63 and/or p73. Particularly relevant are the apoptosis stimulating protein of p53 (ASPP) family proteins, ASPP1 and ASPP2, that have been shown to bind to and stimulate the apoptotic function of p63 and p73 (Bergamaschi et al., 2004) as had been previously shown for p53 (Samuels-Lev et al., 2001) . As the ASPP2 protein binds to the core-DBD of p53, it is quite likely that the central regions of p63 and p73 are also where ASPP proteins interact (Gorina and Pavletich, 1996) . It would therefore be interesting to determine whether the stimulation of p63/p73 by ASPP proteins can also be negatively affected by mutant p53. If so, mutant p53 may have a dual impact on p63/p73 by both blocking their interaction with DNA and some regulatory proteins such as the ASPPs. Other proteins have also been shown to interact with p63 and p73 including YAP and SSRP1 although they do not apparently interact with their core domains (Strano et al., 2001; Zeng et al., 2002) . It cannot be excluded that mutant p53 may counteract these interactors or, reciprocally, they may modulate the ability of mutant p53 to downregulate p63 and p73. Thus, further studies may reveal a second level of regulation of p63 and p73 by mutant p53 by affecting their interactions with other proteins.
Do mutations within the central domains of p63 and p73 affect the activity of wild-type p53? Although mutations in p63/p73 genes are not readily found in cancer, p63 gene mutations are associated with at least five inherited human developmental diseases that display phenotypes such as limb malformation, facial cleft and ectodermal dysplasia (reviewed by Brunner et al., 2002) . Of note, germline mutations found in one of these syndromes, the ectrodactyly-ectodermal dysplasia clefting, are clustered in the DBD of p63. More strikingly, many of these mutations correspond exactly to the hotspot mutants in p53 gene: p63 R204, R279, R280 and R304 mutants are analogous to p53 R175, R248, R249 and R273, respectively. As with p53, such mutants abolish the ability of p63 to interact with DNA (reviewed by van Bokhoven and Brunner, 2002) . As p63 and p73 can bind each other through their OD, it is possible that these p63 mutants may serve as dominant-negative regulators of p73 as well as p63 (Davison et al., 1999) . In addition, it will also be of interest to test whether these p63 mutants can reciprocally bind to and regulate p53.
Clinical implications
As p73 and p63 are involved in both DNA damage induced apoptosis and may be implicated in tumor suppression, efforts aimed at liberating p63/p73 from blockade by mutant p53 might have therapeutic values in cancer treatment. Such approaches can include downregulating mutant p53 via siRNA technology, overexpressing the proapoptotic p63/p73 proteins or disrupting the direct protein-protein interaction between mutant p53 and p63/p73 using peptidomimetics or small molecules (Figure 1 ). Of note, those small molecular compounds that can reactivate mutant p53 by restoring it to wild-type conformation can also potentially release p63/p73 (reviewed by Wiman, 2006) . Such compounds are potentially exciting as they may achieve the dual purpose of bringing back the activity of both p53 and its family members. In summary, results obtained from cell culture, mouse models and clinical correlation have implied that some mutant p53 proteins have gained a novel function by inactivating p63/p73. These studies have pointed the way towards future basic and translational research directions. It is hoped that upcoming studies will shed new light on the meaning of mutant p53 regulation of its siblings p63 and p73. target genes: p21, Bax, Puma, Noxa, etc.
Downregulating mutant p53
Overexpressing p63/p73
Blocking mutant p53 interaction with p63/p73 using peptidomimetics or small molecules Figure 1 Strategies to overcome mutant p53 interaction with p63/p73. Multiple approaches can be exploited to enhance the activity of p63/p73, including ablating the expression of mutant p53 proteins, overexpressing p63/p73 proteins, or disrupting the physical interaction between p53 and p63/p73 with peptidometics or small molecules.
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